Mindset Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022 Life Science Investing
Allergan Aesthetics publishes 'The Future of Aesthetics' global trends report Pharmaceutical Investing
Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder Life Science Investing
Naturally Splendid Reports Second Quarter Results for 2022 and Strategic Update Life Science Investing
Ambrx Biopharma Inc. Reports 1H 2022 Financial Results and Provides Corporate Update Life Science Investing
Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022 Pharmaceutical Investing
AbbVie Showcases New Analyses and Real-World Data Across Multiple Immune-Mediated Skin Diseases at the European Academy of Dermatology and Venereology 2022 Congress Pharmaceutical Investing
NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® WAS WELL-TOLERATED FOR MORE THAN 8 YEARS Market News
Late-Breaking Results From Phase 2 AXIOMATIC-SSP Study of Milvexian, an Investigational Oral Factor XIa Inhibitor, Show Favorable Antithrombotic Profile in Combination With Dual Antiplatelet Therapy Pharmaceutical Investing
Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment Conference Life Science Investing
